Deferasirox (ICL670) is clinically effective and generally well tolerated, and demonstrates dose-responsiveness [7]

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)775-776
Number of pages2
JournalBlood
Volume108
Issue number2
Publication statusPublished - Jul 15 2006

ASJC Scopus subject areas

  • Hematology

Cite this